Advertisement
Screener

EMERGENT BIOSOLUTIONS INC. (EBS) Increase (Decrease) in Accounts Receivable

2.8 / 5 stars · 68/120 Roast Me

EMERGENT BIOSOLUTIONS INC. Increase (Decrease) in Accounts Receivable

EMERGENT BIOSOLUTIONS INC. (EBS) reported Increase (Decrease) in Accounts Receivable of $107.70 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-06

  • EMERGENT BIOSOLUTIONS INC. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $68.80M.
  • EMERGENT BIOSOLUTIONS INC. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $38.90M, a 46.93% decline year-over-year.
  • EMERGENT BIOSOLUTIONS INC. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was -$51.90M, a 167.32% decline year-over-year.
  • EMERGENT BIOSOLUTIONS INC. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $71.60M.
  • EMERGENT BIOSOLUTIONS INC. increase (decrease) in accounts receivable for fiscal 2025 was -$25.50M, a 204.51% decline from fiscal 2024.
  • EMERGENT BIOSOLUTIONS INC. increase (decrease) in accounts receivable for fiscal 2024 was $24.40M, a 12.96% increase from fiscal 2023.
  • EMERGENT BIOSOLUTIONS INC. increase (decrease) in accounts receivable for fiscal 2023 was $21.60M.
  • EMERGENT BIOSOLUTIONS INC. increase (decrease) in accounts receivable for fiscal 2022 was -$118.10M, a 829.01% decline from fiscal 2021.
Period endIncrease (Decrease) in Accounts Receivable 3 monthIncrease (Decrease) in Accounts Receivable 3 month as first filedIncrease (Decrease) in Accounts Receivable 6 monthIncrease (Decrease) in Accounts Receivable 6 month as first filedIncrease (Decrease) in Accounts Receivable 9 monthIncrease (Decrease) in Accounts Receivable 9 month as first filedIncrease (Decrease) in Accounts Receivable 12 monthIncrease (Decrease) in Accounts Receivable 12 month as first filed
2026-06-30$68.80M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
$107.70M
10-Q · filed 2026-08-06
$55.80M
derived: sum of 3 quarters · filed 2026-08-06
$127.40M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31$38.90M
10-Q · filed 2026-05-01
-$13.00M
derived: sum of 2 quarters · filed 2026-05-01
$58.60M
derived: sum of 3 quarters · filed 2026-05-01
-$59.90M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31-$51.90M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27
$19.70M
derived: sum of 2 quarters · filed 2026-02-27
-$98.80M
derived: sum of 3 quarters · filed 2026-08-06
-$25.50M
10-K · filed 2026-02-27
2025-09-30$71.60M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30
-$46.90M
derived: sum of 2 quarters · filed 2026-08-06
$26.40M
10-Q · filed 2025-10-30
$103.50M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30-$118.50M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
-$45.20M
10-Q · filed 2026-08-06
$31.90M
derived: sum of 3 quarters · filed 2026-08-06
-$50.40M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31$73.30M
10-Q · filed 2026-05-01
$150.40M
derived: sum of 2 quarters · filed 2026-05-01
$68.10M
derived: sum of 3 quarters · filed 2026-05-01
$47.70M
derived: sum of 4 quarters · filed 2026-05-01
2024-12-31$77.10M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27
-$5.20M
derived: sum of 2 quarters · filed 2026-02-27
-$25.60M
derived: sum of 3 quarters · filed 2026-02-27
$24.40M
10-K · filed 2026-02-27
2024-09-30-$82.30M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30
-$102.70M
derived: sum of 2 quarters · filed 2025-10-30
-$52.70M
10-Q · filed 2025-10-30
-$89.60M
derived: sum of 4 quarters · filed 2026-02-27
2024-06-30-$20.40M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07
$29.60M
10-Q · filed 2025-08-07
-$7.30M
derived: sum of 3 quarters · filed 2026-02-27
-$78.60M
derived: sum of 4 quarters · filed 2026-02-27
2024-03-31$50.00M
10-Q · filed 2025-05-08
$13.10M
derived: sum of 2 quarters · filed 2026-02-27
-$58.20M
derived: sum of 3 quarters · filed 2026-02-27
$74.20M
derived: sum of 4 quarters · filed 2026-02-27
2023-12-31-$36.90M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27
-$108.20M
derived: sum of 2 quarters · filed 2026-02-27
$24.20M
derived: sum of 3 quarters · filed 2026-02-27
$21.60M
10-K · filed 2026-02-27
2023-09-30-$71.30M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07
$61.10M
derived: sum of 2 quarters · filed 2024-11-07
$58.50M
10-Q · filed 2024-11-07
$22.90M
derived: sum of 4 quarters · filed 2025-03-04
2023-06-30$132.40M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07
$129.80M
10-Q · filed 2024-08-07
$130.60M
10-Q · filed 2023-08-09
$94.20M
derived: sum of 3 quarters · filed 2025-03-04
$109.40M
derived: sum of 4 quarters · filed 2025-03-04
2023-03-31-$2.60M
10-Q · filed 2024-05-02
-$1.80M
10-Q · filed 2023-05-10
-$38.20M
derived: sum of 2 quarters · filed 2025-03-04
-$23.00M
derived: sum of 3 quarters · filed 2025-03-04
-$27.00M
derived: sum of 4 quarters · filed 2025-03-04
2022-12-31-$35.60M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04
-$20.40M
derived: sum of 2 quarters · filed 2025-03-04
-$24.40M
derived: sum of 3 quarters · filed 2025-03-04
-$118.10M
10-K · filed 2025-03-04
-$114.70M
10-K · filed 2023-03-01
2022-09-30$15.20M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-12-11
$11.20M
derived: sum of 2 quarters · filed 2023-12-11
-$82.50M
10-Q · filed 2023-12-11
-$76.20M
10-Q · filed 2022-11-09
-$181.00M
derived: sum of 4 quarters · filed 2024-03-08
2022-06-30-$4.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09
-$97.70M
10-Q · filed 2023-08-09
-$196.20M
derived: sum of 3 quarters · filed 2024-03-08
-$116.20M
derived: sum of 4 quarters · filed 2024-03-08
2022-03-31-$93.70M
10-Q · filed 2023-05-10
-$192.20M
derived: sum of 2 quarters · filed 2024-03-08
-$112.20M
derived: sum of 3 quarters · filed 2024-03-08
-$35.40M
derived: sum of 4 quarters · filed 2024-03-08
2021-12-31-$98.50M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08
-$18.50M
derived: sum of 2 quarters · filed 2024-03-08
$58.30M
derived: sum of 3 quarters · filed 2024-03-08
$16.20M
10-K · filed 2024-03-08
$48.20M
10-K · filed 2022-02-25
2021-09-30$80.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09
$156.80M
derived: sum of 2 quarters · filed 2022-11-09
$114.70M
10-Q · filed 2022-11-09
$161.80M
derived: sum of 4 quarters · filed 2023-12-11
2021-06-30$76.80M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02
$34.70M
10-Q · filed 2022-08-02
$81.80M
derived: sum of 3 quarters · filed 2023-12-11
$19.30M
derived: sum of 4 quarters · filed 2023-12-11
2021-03-31-$42.10M
10-Q · filed 2022-04-29
$5.00M
derived: sum of 2 quarters · filed 2023-12-11
-$57.50M
derived: sum of 3 quarters · filed 2023-12-11
$38.60M
derived: sum of 4 quarters · filed 2023-12-11
2020-12-31$47.10M
derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-12-11
-$15.40M
derived: sum of 2 quarters · filed 2023-12-11
$80.70M
derived: sum of 3 quarters · filed 2023-12-11
-$27.50M
10-K/A · filed 2023-12-11
-$49.00M
10-K · filed 2021-02-19
2020-09-30-$62.50M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05
$33.60M
derived: sum of 2 quarters · filed 2021-11-05
-$74.60M
10-Q · filed 2021-11-05
-$85.00M
derived: sum of 4 quarters · filed 2022-02-25
2020-06-30$96.10M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-30
-$12.10M
10-Q · filed 2021-07-30
-$22.50M
derived: sum of 3 quarters · filed 2022-02-25
$40.70M
derived: sum of 4 quarters · filed 2022-02-25
2020-03-31-$108.20M
10-Q · filed 2021-04-30
-$118.60M
derived: sum of 2 quarters · filed 2022-02-25
-$55.40M
derived: sum of 3 quarters · filed 2022-02-25
$41.60M
derived: sum of 4 quarters · filed 2022-02-25
2019-12-31-$10.40M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25
$52.80M
derived: sum of 2 quarters · filed 2022-02-25
$149.80M
derived: sum of 3 quarters · filed 2022-02-25
$8.20M
10-K · filed 2022-02-25
2019-09-30$63.20M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06
$160.20M
derived: sum of 2 quarters · filed 2020-11-06
$18.60M
10-Q · filed 2020-11-06
$179.30M
derived: sum of 4 quarters · filed 2021-02-19
2019-06-30$97.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31
-$44.60M
10-Q · filed 2020-07-31
$116.10M
derived: sum of 3 quarters · filed 2021-02-19
$3.40M
derived: sum of 4 quarters · filed 2021-02-19
2019-03-31-$141.60M
10-Q · filed 2020-05-01
$19.10M
derived: sum of 2 quarters · filed 2021-02-19
-$93.60M
derived: sum of 3 quarters · filed 2021-02-19
-$25.60M
derived: sum of 4 quarters · filed 2021-02-19
2018-12-31$160.70M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-19
$48.00M
derived: sum of 2 quarters · filed 2021-02-19
$116.00M
derived: sum of 3 quarters · filed 2021-02-19
$94.20M
10-K · filed 2021-02-19
2018-09-30-$112.70M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07
-$44.70M
derived: sum of 2 quarters · filed 2019-11-07
-$66.50M
10-Q · filed 2019-11-07
-$66.45M
10-Q · filed 2018-11-02
-$52.29M
derived: sum of 4 quarters · filed 2020-02-25
2018-06-30$68.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-02
$46.20M
10-Q · filed 2019-08-02
$46.25M
10-Q · filed 2018-08-03
$60.41M
derived: sum of 3 quarters · filed 2020-02-25
$87.16M
derived: sum of 4 quarters · filed 2020-02-25
2018-03-31-$21.80M
10-Q · filed 2019-05-08
-$21.82M
10-Q · filed 2018-05-04
-$7.59M
derived: sum of 2 quarters · filed 2020-02-25
$19.16M
derived: sum of 3 quarters · filed 2020-02-25
-$6.44M
derived: sum of 4 quarters · filed 2020-02-25
2017-12-31$14.21M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25
$40.96M
derived: sum of 2 quarters · filed 2020-02-25
$15.36M
derived: sum of 3 quarters · filed 2020-02-25
$4.80M
10-K · filed 2020-02-25
$4.81M
10-K · filed 2018-02-23
2017-09-30$26.75M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-02
$1.15M
derived: sum of 2 quarters · filed 2018-11-02
-$9.41M
10-Q · filed 2018-11-02
$58.02M
derived: sum of 4 quarters · filed 2019-02-22
2017-06-30-$25.60M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03
-$36.16M
10-Q · filed 2018-08-03
$31.27M
derived: sum of 3 quarters · filed 2019-02-22
$40.17M
derived: sum of 4 quarters · filed 2019-02-22
2017-03-31-$10.56M
10-Q · filed 2018-05-04
$10.56M
10-Q · filed 2017-05-05
$56.87M
derived: sum of 2 quarters · filed 2019-02-22
$65.77M
derived: sum of 3 quarters · filed 2019-02-22
-$39.37M
derived: sum of 4 quarters · filed 2019-02-22
2016-12-31$67.44M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22
$76.33M
derived: sum of 2 quarters · filed 2019-02-22
-$28.81M
derived: sum of 3 quarters · filed 2019-02-22
$22.40M
10-K · filed 2019-02-22
$22.45M
10-K · filed 2017-02-28
2016-09-30$8.90M
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03
-$96.24M
derived: sum of 2 quarters · filed 2017-11-03
-$45.03M
10-Q · filed 2017-11-03
$45.03M
10-Q · filed 2016-11-09
$17.57M
derived: sum of 4 quarters · filed 2018-02-23
2016-06-30-$105.14M
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-04
-$53.93M
10-Q · filed 2017-08-04
$8.67M
derived: sum of 3 quarters · filed 2018-02-23
-$30.47M
derived: sum of 4 quarters · filed 2018-02-23
2016-03-31$51.21M
10-Q · filed 2017-05-05
-$51.21M
10-Q · filed 2016-05-06
$113.81M
derived: sum of 2 quarters · filed 2018-02-23
$74.67M
derived: sum of 3 quarters · filed 2018-02-23
$110.33M
derived: sum of 4 quarters · filed 2018-02-23
2015-12-31$62.60M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23
$23.47M
derived: sum of 2 quarters · filed 2018-02-23
$59.13M
derived: sum of 3 quarters · filed 2018-02-23
$64.35M
10-K · filed 2018-02-23
2015-09-30-$39.13M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09
-$3.48M
derived: sum of 2 quarters · filed 2016-11-09
$1.75M
10-Q · filed 2016-11-09
-$1.75M
10-Q · filed 2015-11-06
$16.45M
derived: sum of 4 quarters · filed 2017-02-28
2015-06-30$35.66M
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05
$40.88M
10-Q · filed 2016-08-05
$55.59M
derived: sum of 3 quarters · filed 2017-02-28
$21.75M
derived: sum of 4 quarters · filed 2017-02-28
2015-03-31$5.22M
10-Q · filed 2016-05-06
$19.93M
derived: sum of 2 quarters · filed 2017-02-28
-$13.91M
derived: sum of 3 quarters · filed 2017-02-28
$1.41M
derived: sum of 4 quarters · filed 2017-02-28
2014-12-31$14.70M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28
-$19.13M
derived: sum of 2 quarters · filed 2017-02-28
-$3.81M
derived: sum of 3 quarters · filed 2017-02-28
-$21.41M
10-K · filed 2017-02-28
2014-09-30-$33.83M
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06
-$18.52M
derived: sum of 2 quarters · filed 2015-11-06
-$36.11M
10-Q · filed 2015-11-06
-$5.61M
derived: sum of 4 quarters · filed 2016-02-29
2014-06-30$15.32M
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06
-$2.27M
10-Q · filed 2015-08-06
$28.22M
derived: sum of 3 quarters · filed 2016-02-29
$3.94M
derived: sum of 4 quarters · filed 2016-02-29
2014-03-31-$17.59M
10-Q · filed 2015-05-08
$12.90M
derived: sum of 2 quarters · filed 2016-02-29
-$11.37M
derived: sum of 3 quarters · filed 2016-02-29
-$19.97M
derived: sum of 4 quarters · filed 2016-02-29
2013-12-31$30.49M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29
$6.22M
derived: sum of 2 quarters · filed 2016-02-29
-$2.38M
derived: sum of 3 quarters · filed 2016-02-29
-$35.46M
10-K · filed 2016-02-29
2013-09-30-$24.28M
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10
-$32.87M
derived: sum of 2 quarters · filed 2014-11-10
-$65.95M
10-Q · filed 2014-11-10
$12.95M
derived: sum of 4 quarters · filed 2015-03-09
2013-06-30-$8.60M
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-08
-$41.67M
10-Q · filed 2014-08-08
$37.22M
derived: sum of 3 quarters · filed 2015-03-09
$7.55M
derived: sum of 4 quarters · filed 2015-03-09
2013-03-31-$33.08M
10-Q · filed 2014-05-12
$45.82M
derived: sum of 2 quarters · filed 2015-03-09
$16.15M
derived: sum of 3 quarters · filed 2015-03-09
$19.31M
derived: sum of 4 quarters · filed 2015-03-09
2012-12-31$78.90M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-09
$49.23M
derived: sum of 2 quarters · filed 2015-03-09
$52.39M
derived: sum of 3 quarters · filed 2015-03-09
$21.89M
10-K · filed 2015-03-09
2012-09-30-$29.67M
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08
-$26.50M
derived: sum of 2 quarters · filed 2013-11-08
-$57.01M
10-Q · filed 2013-11-08
-$31.84M
derived: sum of 4 quarters · filed 2014-03-10
2012-06-30$3.16M
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06
-$27.34M
10-Q · filed 2013-08-06
-$2.17M
derived: sum of 3 quarters · filed 2014-03-10
-$402.00K
derived: sum of 4 quarters · filed 2014-03-10
2012-03-31-$30.50M
10-Q · filed 2013-05-03
-$5.33M
derived: sum of 2 quarters · filed 2014-03-10
-$3.56M
derived: sum of 3 quarters · filed 2014-03-10
$31.72M
derived: sum of 4 quarters · filed 2014-03-10
2011-12-31$25.17M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-10
$26.94M
derived: sum of 2 quarters · filed 2014-03-10
$62.22M
derived: sum of 3 quarters · filed 2014-03-10
$34.87M
10-K · filed 2014-03-10
2011-09-30$1.77M
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-01
$37.05M
derived: sum of 2 quarters · filed 2012-11-01
$9.71M
10-Q · filed 2012-11-01
-$9.67M
10-Q · filed 2011-11-04
-$56.32M
derived: sum of 4 quarters · filed 2013-03-08
2011-06-30$35.29M
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-03
$7.94M
10-Q · filed 2012-08-03
-$7.94M
10-Q · filed 2011-08-05
-$58.09M
derived: sum of 3 quarters · filed 2013-03-08
-$20.26M
derived: sum of 4 quarters · filed 2013-03-08
2011-03-31-$27.35M
10-Q · filed 2012-05-04
-$93.38M
derived: sum of 2 quarters · filed 2013-03-08
-$55.55M
derived: sum of 3 quarters · filed 2013-03-08
2010-12-31-$66.03M
derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-08
-$28.20M
derived: sum of 2 quarters · filed 2013-03-08
-$19.09M
10-K · filed 2013-03-08
2010-09-30$37.83M
derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04
$46.94M
10-Q · filed 2011-11-04
2010-06-30$9.11M
10-Q · filed 2011-08-05
2009-12-31$30.02M
10-K · filed 2012-03-09

Similar stocks

Stock NameCountryMarket CapPE Ratio
ENANTA PHARMACEUTICALS INC (ENTA)United States$0.349B-6.72
Larimar Therapeutics, Inc. (LRMR)United States$0.344B-1.83
Vogenx, Inc. (VOGX)United States$0.355B
Benitec Biopharma Inc. (BNTC)United States$0.337B-10.08
BioAge Labs, Inc. (BIOA)United States$0.333B-11.88
BridgeBio Oncology Therapeutics, Inc. (BBOT)United States$0.320B-3.35
Evommune, Inc. (EVMN)United States$0.320B-5.10
Prelude Therapeutics Inc (PRLD)United States$0.318B-7.01
ABEONA THERAPEUTICS INC. (ABEO)United States$0.312B-5.63
Rezolute, Inc. (RZLT)United States$0.382B-6.45